Link to this page
Physician Data Query
Last uploaded:
August 28, 2024
Jump to:
| Preferred Name | gliclazide | |
| Synonyms |
1-(3-azabicyclo(3.3.0)Oct-3-Yl)-3-(P-tolylsulfonyl)urea |
|
| Definitions |
A short-acting, relatively high-potency, second-generation sulfonylurea compound with hypoglycemic activity. Gliclazide also increases peripheral insulin sensitivity. This agent is metabolized by CYP2C9. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C87618" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C87618" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000775359 |
|
| altLabel |
1-(3-azabicyclo(3.3.0)Oct-3-Yl)-3-(P-tolylsulfonyl)urea
|
|
| CAS Registry |
21187-98-4
|
|
| cui |
C0017631
|
|
| DATE FIRST PUBLISHED |
2015-09-04
|
|
| Date last modified |
2015-09-04
|
|
| definition |
A short-acting, relatively high-potency, second-generation sulfonylurea compound with hypoglycemic activity. Gliclazide also increases peripheral insulin sensitivity. This agent is metabolized by CYP2C9. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C87618" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C87618" NCI Thesaurus)
|
|
| NCI ID |
C87618
|
|
| notation |
CDR0000775359
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
gliclazide
|
|
| tui |
T109 T121
|
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping